The NHS Confederation has appointed Niall Dickson as its new chief executive. Niall has just completed seven years as chief executive of the General Medical Council (GMC) and before that was chief executive of The King's Fund. He was for many years the BBC's social affairs editor. During his time at the GMC from 2010 to 2016, Niall delivered a raft of reforms. These included an expansion of its responsibilities for medical education and training, the introduction of revalidation in 2012, the introduction of language checks for doctors from Europe in 2014, and the establishment of the Medical Practitioners Tribunal Service to provide a clear separation between the GMC's investigation of complaints and the adjudication of hearings.
Adherium has appointed Scott Fleming as senior vice president of business development, Europe. Scott is a founding member of the digital drug delivery movement. After gaining an interest in drug delivery at PA Consulting in the US, he co-founded MicroDose Therapeutx in 1997, developing the first totally digital piezo driven dry powder inhaler, which was then licensed to big pharma. During his tenure as senior vice president, he led MicroDose's strategy and executed numerous licensing and development collaborations with Bristol-Myers Squibb, Novartis, Merck & Co and Gilead Sciences, among others, for respiratory programmes using the digital inhaler and associated in-house molecules. Scott engineered the sale of MicroDose to Teva in 2013, and subsequently took on a key role as the global brand lead for eConnectivity of Teva's respiratory franchise based in Amsterdam.
e-Therapeutics has appointed Raymond Barlow as CEO. Raymond is currently executive director of corporate development at Amgen, based in Switzerland. He brings to e-Therapeutics broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included scientific, business and corporate roles with Astra Zeneca, Crucell and Johnson & Johnson. He will be relocating to Oxford.
Congenica has expanded its operations in the US with the appointment of Shikha O’Brien as its chief business officer. Shikha will be based out of San Diego, California, where she will oversee the global sales and marketing operations. San Diego will be Congenica’s first office outside of the UK, with plans to establish another one on the east coast. Her previous roles included establishing start-ups and bringing innovative solutions in the Life Sciences and Healthcare informatics.
Oxular, an Oxford-based retinal therapeutics company, has named David Fellows, previously non-executive director, as the company’s chairman of the Board. David is currently CEO of NightstaRx, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies. He was previously vice president of Johnson & Johnson’s Vision Care franchise.
International healthcare strategy and communications agency Cognite, based in London and Zurich, has appointed Cassandra Johnson as account director. Having gained several years of valuable experience with agencies such as CDM and Cherry, Cassandra will be working from Cognite's new office in Golden Square, Soho. Meanwhile, David Sartain has joined Cognite as a senior art director. David has spent 18 years in advertising, working in a number of sectors, including pharmaceuticals.
The Supervisory Board of MorphoSys has appointed Malte Peters to be its new chief development officer. He joins MorphoSys from Novatis company Sandoz, where he serves as global head of clinical development, biopharmaceuticals. Malte built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis, where he focused on the management of clinical development projects in the field of oncology. Before that, he served in positions as medical director at Micromet and as head of translational research and pharmacogenomics at German pharmaceutical company Merck KGaA.
Albumedix has appointed Giles Campion as chief medical officer. Prior to joining Albumedix, Giles was senior vice president of research and development and CMO at Prosensa Holdings and then group vice president, Neuromuscular Franchise at Biomarin following the Prosensa acquisition. Previously he had held positions such as global head of clinical research and development at General Electric Healthcare and European head of exploratory clinical development at Novartis. With experience across multiple therapeutic areas, most recently in orphan neuromuscular disorders, he has overseen global and regional filing and approvals of new products in cardiovascular diseases, diabetes, oncology, neurodegenerative diseases and hormone deficiency. During his career he has been responsible for the development of over 40 therapeutics and diagnostic agents.
ObsEva has named Timothy Adams as CFO. Timothy has over 30 years of industry experience and most recently served as executive vice president and CFO of Demandware. Previously he served as senior vice president and CFO of athenahealth, chief investment officer of Constitution Medical Investors and CFO at a number of companies including Cytyc Corporation and Dige.
Mithra Pharmaceuticals, a company focused on women's health, has appointed Christophe Maréchal as chief financial officer. Christophe is currently director of group treasury and credit risk management at Hamon Group, an engineering and contracting company. He has more than 20 years of financial experience in the international industrial, telecommunications, manufacturing and banking industries, including M&A, operational and financial strategy.
British artificial intelligence company BenevolentAI has appointed Dr Patrick Keohane as chief medical officer, becoming the first AI company to have a CMO on its staff. Patrick will take up the position of CMO of BenevolentBio – a subsidiary of BenevolentAI that applies its technology to accelerate a pipeline of better medicines for patients and to explore further applications for AI in bioscience. He will work with BenevolentBio’s expanding team of experienced drug discovery scientists, technology experts and bioscience researchers to rapidly identify and progress novel therapies into early and late stage clinical trials. Patrick has held senior management positions in research and development at Eli Lilly and AstraZeneca. He joins the company from Glenmark Pharmaceuticals, where he held the position of chief medical officer.
Targovax, a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, has appointed Erik Digman Wiklund as chief financial officer. Erik joins from the nutraceutical company Aker Biomarine Antarctic, where he held the position of director of product innovation. Prior to joining Aker Biomarine, Erik worked for Norwegian cancer biotechnology company Algeta, and also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Australia.
Aelix Therapeutics, a drug development company that specialises in the discovery and development of immunotherapies that target HIV infection, has appointed Philippe Monteyne as an independent member of its board of directors. Philippe is a partner at Fund+ in Belgium and he has also been a visiting professor of neurosciences at UCL, Catholic University of Louvain in Belgium and vice president of R&D at Sanofi France. Prior to his time there, Philippe served as senior vice president, head of development, and CMO at GSK Rare Diseases.